Loading...
CStone Pharmaceuticals
2616.HK•HKSE
Healthcare
Biotechnology
HK$7.52
HK$0.78(11.57%)
CStone Pharmaceuticals (2616.HK) Financial Performance & Income Statement Overview
Analyze CStone Pharmaceuticals (2616.HK) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Revenue Growth
-12.21%
↓ 12.21%
Operating Income Growth
82.85%
↑ 82.85%
Net Income Growth
75.16%
↑ 75.16%
Operating Cash Flow Growth
100.00%
↑ 100.00%
Operating Margin
-26.05%
↓ 26.05%
Gross Margin
58.98%
↑ 58.98%
Net Profit Margin
-22.40%
↓ 22.40%
ROE
-21.94%
↓ 21.94%
ROIC
-14.91%
↓ 14.91%
CStone Pharmaceuticals (2616.HK) Income Statement & Financial Overview
Explore comprehensive income reports for CStone Pharmaceuticals 2616.HK, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $76.52M | $76.52M | $127.08M | $127.08M |
| Cost of Revenue | $42.46M | $42.46M | $41.07M | $41.07M |
| Gross Profit | $34.06M | $34.06M | $86.01M | $86.01M |
| Gross Profit Ratio | $0.45 | $0.45 | $0.68 | $0.68 |
| R&D Expenses | $34.20M | $34.20M | $33.12M | $33.12M |
| SG&A Expenses | $51.07M | $51.07M | $54.72M | $54.72M |
| Operating Expenses | $85.27M | $85.27M | $87.84M | $87.84M |
| Total Costs & Expenses | $127.73M | $127.73M | $128.91M | $128.91M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $4.73M | $3.44M | $3.44M | $3.44M |
| EBITDA | -$41.12M | -$42.41M | $1.61M | $1.61M |
| EBITDA Ratio | -$0.54 | -$0.55 | $0.01 | $0.01 |
| Operating Income | -$51.21M | -$51.21M | -$1.83M | -$1.83M |
| Operating Income Ratio | -$0.67 | -$0.67 | -$0.01 | -$0.01 |
| Other Income/Expenses (Net) | -$2.24M | -$2.24M | $9.68M | $9.68M |
| Income Before Tax | -$53.45M | -$53.45M | $7.85M | $7.85M |
| Income Before Tax Ratio | -$0.70 | -$0.70 | $0.06 | $0.06 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$53.45M | -$53.45M | $7.85M | $7.85M |
| Net Income Ratio | -$0.70 | -$0.70 | $0.06 | $0.06 |
| EPS | -$0.04 | -$0.04 | $0.005 | $0.005 |
| Diluted EPS | -$0.04 | -$0.04 | $0.006 | $0.006 |
| Weighted Avg Shares Outstanding | $1.28B | $1.28B | $1.57B | $1.57B |
| Weighted Avg Shares Outstanding (Diluted) | $1.28B | $1.28B | $1.28B | $1.28B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan